Weight loss efficiency and safety of tirzepatide: A Systematic review

Lin, Fei; Yu, Bin; Ling, Baodong; Lv, Guangyao; Shang, Huijun; Zhao, Xia; Jie, Xiaoling; Chen, Jing; Li, Yan

doi:10.1371/journal.pone.0285197

Cited by 10 publications

(10 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These reactions are not signi cantly different from those caused by GLP-1RAs. Additionally, gastrointestinal reactions to TZP tend to decrease over time [39][40][41][42] . Simultaneously, the use of TZP signi cantly increased the incidence of gallbladder and biliary diseases, but did not elevate the risk of pancreatitis [43] .…”

Section: Discussionmentioning

confidence: 99%

Tirzepatide cardiovascular benefits and adverse events assessment: a Bayesian network meta-analysis

gong,

cheng,

han

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective To comprehensively assess the cardiovascular benefits and adverse events of tirzepatide (including different control groups, different dosages and different patients). Method A systematic search was conducted on PubMed, Web of Science,The Cochrane Library and ClinicalTrials.gov. Randomized controlled trials (RCTs) of at least 26 weeks that compared tirzepatide (TZP) at doses of 5mg, 10mg, and 15 mg once weekly with another antihyperglycemic drug or placebo in adults with obesity or type 2 dabetes mellitus(T2DM) were included. Data Synthesis was performed using R 4.2.2 and Stata 18.0 software. Each outcome was presented as a relative risk (RR) with a 95% confidence interval (CI). The results were also displayed using network plots, the surface under the cumulative ranking curve value (SUCRA), league table and forest plot. Results A total of 14 RCTs with 14654 participants with T2DM or obesity were included inthis study. Generally, compared to placebo, insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs), TZP did not increase the risk of four-component major adverse cardiovascular events (MACE-4) (RR [95% CI], 0.54[0.25 to 1.06], 0.85 [0.45 to 1.81], 1.00 [0.34 to 2.92], respectively) and significantly increased total adverse events(TAEs)(RR[95% CI], 1.09[1.01,1.19], 1.22 [1.11,1.35], 1.03 [0.91,1.16], respectively). Compared to placebo, TZP 5mg, TZP 10mg and TZP 15mg all reduced the incidence of MACE-4 (RR [95% CI], 0.47 [0.23 to 1.12], 0.46 [0.15 to 1.48], 0.38 [0.17 to 0.84], respectively) and increased the risk of TAEs (RR[95% CI] 1.04[0.96,1.13], 1.07[0.99,1.16], 1.10[1.02,1.19], respectively). Compared to GLP-1 RAs, TZP 5 mg, TZP 10 mg, and TZP 15 mg all increased the risk of TAEs(RR [95% CI], 1.01[0.91,1.11], 1.04[0.94,1.14], 1.07[0.97,1.17], respectively) and TZP 15mg reduced the risk of MACE-4 (0.82 [0.31 to 2.22]). Compared to obesity, patients with T2DM experienced greater benefits of MACE-4 (RR[95% CI], 0.44[0.04 to 2.65])and lower risk of TAEs (RR [95% CI], 0.95 [0.77 to 1.24]). Additionlay, TZP reduced all-cause death (ACD) and serious adverse events(SAEs) but increased the risk of DAEs. And these benefits were not superior to those of GLP-1RAs, while the risk of adverse events leading to discontinuation of study treatment (DAEs) was higher than that of GLP-1RAs. TZP 15mg was more effective in reducing ACD and SAEs, but also increased the risk of discontinuation. among patients who use TZP, T2DM patients had greater benefits in ACD and less risk of SAEs and DAEs compared to obeity patients. Conclusions TZP is not inferior to GLP-1 RAs in reducing cardiovascular events. The effect is greater with TZP 15mg, but there are also more adverse events. Additionally, the use of TZP in T2DM patients may have a greater effect and fewer adverse events than in obesity patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Tirzepatide cardiovascular benefits and adverse events assessment: a Bayesian network meta-analysis

gong,

cheng,

han

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Currently, Mounjaro® is available in the following doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg [ 32 ]. In pharmacokinetic studies, it was found that the mean half-life was 116.7 h (5 days); hence, the most optimal and practiced form of dosing is weekly subcutaneous injections of the drug [ 29 ].…”

Section: Tirzepatidementioning

confidence: 99%

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management

Wojtara,

Mazumder,

Syeda

et al. 2023

Advances in Medicine

View full text Add to dashboard Cite

Rates of obesity have risen over the past few decades. Subsequently, the popularity of the pharmaceutical weight-loss drug market has grown over the past few years to meet growing demand. Among the most commonly prescribed drugs for weight management, many are glucagon-like peptide-1 receptor agonists (GLP-1 agonists) which are also utilized for the management of type 2 diabetes. There is a substantial and growing body of research comparing the efficacy of different clinical trials and examining long-term safety. This literature review examines the rise of off-label prescribing practices in the management of weight, with a focus on GLP-1 agonists. Physicians and patients should be aware of the unique aspects of existing treatment options, the impacts of off-label prescribing, and the effects of these medications. This review emphasizes the importance of informed decision-making, as well as the need for further research to guide future clinical practice.

show abstract

“…Three systematic reviews and meta-analyses have been published in 2023, documenting the weight loss benefits of tirzepatide (Lin et al, 2023;Rohani et al, 2023;Tan et al, 2023), with one drawing attention to the need for vigilance regarding gastrointestinal adverse effects (Lin et al, 2023).…”

Section: Dual Incretin Agonistsmentioning

confidence: 99%

Newer pharmacological interventions directed at gut hormones for obesity

Camilleri,

Acosta

2023

British J Pharmacology

View full text Add to dashboard Cite

The objective is to review the newer pharmacological interventions for obesity, specifically single, dual, and triple incretin receptor agonists that are either available or in the pipeline for treatment of obesity. The three incretin receptor targets are glucagon like peptide‐1 (GLP‐1), glucose‐dependent insulinotropic peptide (GIP), and glucagon. There are several approved single or dual incretin agonists which are administered subcutaneously daily (e.g., liraglutide) or weekly (e.g., semaglutide, dulaglutide, and exenatide QW), and experimental dual or triple incretin agonists. Other analogs of amylin, peptide YY, and oxyntomodulin, as well as a combination GLP1R agonist and GIPR antagonist are also being developed. Oral semaglutide (administered daily) is approved for type 2 diabetes and is on track for regulatory review for obesity. The review includes specifically perspectives on the effects of these mechanisms and pharmacological agents on gastric emptying which contribute to satiation and weight loss, in addition to the established evidence on effects on central mechanisms controlling appetite. In the future, it is anticipated that small molecule GLP‐1 receptor agonists (e.g., oral danuglipron) will be developed. These pharmacological agents are having significant impact on glycemic control and obesity and their co‐morbidities.

show abstract

Weight loss efficiency and safety of tirzepatide: A Systematic review

Cited by 10 publications

References 45 publications

Tirzepatide cardiovascular benefits and adverse events assessment: a Bayesian network meta-analysis

Tirzepatide cardiovascular benefits and adverse events assessment: a Bayesian network meta-analysis

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management

Newer pharmacological interventions directed at gut hormones for obesity

Contact Info

Product

Resources

About